David Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer Ventures. The Cambridge, MA-based effort, dubbed Cydan, will scout out promising early-stage assets and mold them into pipeline programs for evenutal spin-out into new biotech companies. Report